Gary D. Hutchins

Gary D. Hutchins

Auto-generated profile, based on publicly available information

Gary D. Hutchins

Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Current Oncology Reports
Verified
Journal Article
Open access
PDF file
WOWynton B. Overcast
Wynton B. Overcast
KDKorbin M. Davis
Korbin M. Davis
CHChang Y. Ho
Chang Y. Ho
GHGary D. Hutchins
Gary D. Hutchins
MGMark A. Green
Mark A. Green
MVMichael Veronesi
Michael Veronesi
Purpose of Review: This review will explore the latest in advanced imaging techniques, with a focus on the complementary nature of multiparametric, multimodality imaging using magnetic resonance imaging (MRI) and positron emission tomography (PET). Recent Findings: Advanced MRI techniques including perfusion-weighted imaging (PWI), MR spectroscopy (MRS), diffusion-weighted imaging (DWI), and MR chemical exchange saturation transfer (CEST) offer significant advantages over conventional MR imaging when evaluating tumor extent, predicting grade, and assessing treatment response. PET performed in addition to advanced MRI provides complementary information regarding tumor metabolic properties, particularly when performed simultaneously. 18F-fluoroethyltyrosine (FET) PET improves the specificity of tumor diagnosis and evaluation of post-treatment changes. Incorporation of radiogenomics and machine learning methods further improve advanced imaging. Summary: The complementary nature of combining advanced imaging techniques across modalities for brain tumor imaging and incorporating technologies such as radiogenomics has the potential to reshape the landscape in neuro-oncology.

1 January 2008 in ILAR Journal
Verified
Journal Article
Open access
PDF file
GHGary D. Hutchins
Gary D. Hutchins
MMMichael A. Miller
Michael A. Miller
VSVictor C. Soon
Victor C. Soon
TRTimothy Receveur
Timothy Receveur
Positron emission tomography (PET) is well established as an important research and clinical molecular imaging modality. Although the size differences between humans and rodents create formidable challenges for the application of PET imaging in small animals, advances in technology over the past several years have enabled the translation of this imaging modality to preclinical applications. In this article we discuss the basic principles of PET instrumentation and radiopharmaceuticals, and examine the key factors responsible for the qualitative and quantitative imaging capabilities of small animal PET systems. We describe the criteria that PET imaging agents must meet, and provide examples of small animal PET imaging to give the reader a broad perspective on the capabilities and limitations of this evolving technology. A crucial driver for future advances in PET imaging is the availability of molecular imaging probes labeled with positron-emitting radionuclides. The strong translational science potential of small animal and human PET holds great promise to dramatically advance our understanding of human disease. The assessment of molecular and functional processes using imaging agents as either direct or surrogate biomarkers will ultimately enable the characterization of disease expression in individual patients and thus facilitate tailored treatment plans that can be monitored for their effectiveness in each subject.

30 June 2014 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
KTKatie N. Tapp
Katie N. Tapp
WLWilliam B. Lea
William B. Lea
MJMatthew S. Johnson
Matthew S. Johnson
MTMark Tann
Mark Tann
JFJames W. Fletcher
James W. Fletcher
GHGary D. Hutchins
Gary D. Hutchins
PET/CT imaging after radioembolization is a viable method for determining the posttreatment (90)Y distribution in the liver. Low true-to-random coincidence ratios in (90)Y PET studies limit the quantitative accuracy of these studies when reconstruction algorithms optimized for traditional PET imaging are used. This study examined these quantitative limitations and assessed the feasibility of generating radiation dosimetry maps in liver regions with high and low (90)Y concentrations. (90)Y PET images were collected on a PET/CT scanner and iteratively reconstructed with the vendor-supplied reconstruction algorithm. PET studies on a Jaszczak cylindric phantom were performed to determine quantitative accuracy and minimum detectable concentration (MDC). (90)Y and (18)F point-source studies were used to investigate the possible increase in detected random coincidence events due to bremsstrahlung photons. Retrospective quantitative analyses were performed on (90)Y PET/CT images obtained after 65 right or left hepatic artery radioembolizations in 59 patients. Quantitative image errors were determined by comparing the measured image activity with the assayed (90)Y activity. PET images were converted to dose maps through convolution with voxel S values generated using MCNPX, a Monte Carlo N-particle transport code system for multiparticle and high-energy applications. Tumor and parenchyma doses and potential bias based on measurements found below the MDC were recorded. Random coincidences were found to increase in (90)Y acquisitions, compared with (18)F acquisitions, at similar positron emission rates because of bremsstrahlung photons. Positive bias was observed in all images. Quantitative accuracy was achieved for phantom inserts above the MDC of 1 MBq/mL. The mean dose to viable tumors was 183.6 ± 156.5 Gy, with an average potential bias of 3.3 ± 6.4 Gy. The mean dose to the parenchyma was 97.1 ± 22.1 Gy, with an average potential bias of 8.9 ± 4.9 Gy. The low signal-to-noise ratio caused by low positron emission rates and high bremsstrahlung photon production resulted in a positive bias on (90)Y PET images reconstructed with conventional iterative algorithms. However, quantitative accuracy was good at high activity concentrations, such as those found in tumor volumes, allowing for adequate tumor (90)Y PET/CT dosimetry after radioembolization.

19 August 2019 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
MGMark A. Green
Mark A. Green
GHGary D. Hutchins
Gary D. Hutchins
CBClinton D. Bahler
Clinton D. Bahler
MTMark Tann
Mark Tann
CMCarla J. Mathias
Carla J. Mathias
JFJames W. Fletcher
James W. Fletcher
Purpose This study was undertaken to evaluate radiation dosimetry for the prostate-specific membrane antigen targeted [68Ga]Ga-P16-093 radiopharmaceutical, and to initially assess agent performance in positron emission tomography (PET) detection of the site of disease in prostate cancer patients presenting with biochemical recurrence. Procedures Under IND 133,222 and an IRB-approved research protocol, we evaluated the biodistribution and pharmacokinetics of [68Ga]Ga-P16-093 with serial PET imaging following intravenous administration to ten prostate cancer patients with biochemical recurrence. The recruited subjects were all patients in whom a recent [68Ga]Ga-PSMA-11 PET/X-ray computed tomography (CT) exam had been independently performed under IND 131,806 to assist in decision-making with regard to their clinical care. Voided urine was collected from each subject at ~ 60 min and ~ 140 min post-[68Ga]Ga-P16-093 injection and assayed for Ga-68 content. Following image segmentation to extract tissue time-activity curves and corresponding cumulated activity values, radiation dosimetry estimates were calculated using IDAC Dose 2.1. The prior [68Ga]Ga-PSMA-11 PET/CT exam (whole-body PET imaging at 60 min post-injection, performed with contrast-enhanced diagnostic CT) served as a reference scan for comparison to the [68Ga]Ga-P16-093 findings. Results [68Ga]Ga-P16-093 PET images at 60 min post-injection provided diagnostic information that appeared equivalent to the subject’s prior [68Ga]Ga-PSMA-11 scan. With both radiopharmaceuticals, sites of tumor recurrence were found in eight of the ten patients, identifying 16 lesions. The site of recurrence was not detected with either agent for the other two subjects. Bladder activity was consistently lower with [68Ga]Ga-P16-093 than [68Ga]Ga-PSMA-11. The kidneys, spleen, salivary glands, and liver receive the highest radiation exposure from [68Ga]Ga-P16-093, with estimated doses of 1.7 × 10−1, 6.7 × 10−2, 6.5 × 10−2, and 5.6 × 10−2 mGy/MBq, respectively. The corresponding effective dose from [68Ga]Ga-P16-093 is 2.3 × 10−2 mSv/MBq. Conclusions [68Ga]Ga-P16-093 provided diagnostic information that appeared equivalent to [68Ga]Ga-PSMA-11 in this limited series of ten prostate cancer patients presenting with biochemical recurrence, with the kidneys found to be the critical organ. Diminished tracer appearance in the urine represents a potential advantage of [68Ga]Ga-P16-093 over [68Ga]Ga-PSMA-11 for detection of lesions in the pelvis.

31 January 2015 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
MAMatthew R Allen
Matthew R Allen
PTPaul Territo
Paul Territo
CLChen Lin
Chen Lin
SPScott Persohn
Scott Persohn
LJLei Jiang
Lei Jiang
GHGary D Hutchins
Gary D Hutchins
Raloxifene positively affects mechanical properties of the bone matrix in part through modification of skeletal‐bound water. The goal of this study was to determine if raloxifene‐induced alterations in skeletal hydration could be measured in vivo using ultra‐short echotime magnetic resonance imaging (UTE‐MRI). Twelve skeletally mature female beagle dogs (n = 6/group) were treated for 6 months with oral doses of saline vehicle (VEH, 1 mL/kg/d) or raloxifene (RAL, 0.5 mg/kg/d). After 6 months of treatment, all animals underwent in vivo UTE‐MRI of the proximal tibial cortical bone. UTE‐MRI signal intensity versus echotime curves were analyzed by fitting a double exponential to determine the short and long relaxation times of water with the bone (dependent estimations of bound and free water, respectively). Raloxifene‐treated animals had significantly higher bound water (+14%; p = 0.05) and lower free water (–20%) compared with vehicle‐treated animals. These data provide the first evidence that drug‐induced changes in skeletal hydration can be noninvasively assessed using UTE‐MRI. © 2015 American Society for Bone and Mineral Research. © 2015 American Society for Bone and Mineral Research.

1 July 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MWMin Wang
Min Wang
MGMingzhang Gao
Mingzhang Gao
BSBrandon L. Steele
Brandon L. Steele
BGBarbara E. Glick-Wilson
Barbara E. Glick-Wilson
CBClive Brown-Proctor
Clive Brown-Proctor
QZQi-Huang Zheng
Qi-Huang Zheng